Terence Flynn: AI Opportunities in Healthcare

Terence Flynn: AI Opportunities in Healthcare

Artificial intelligence could help biopharmaceutical companies reduce costs as well as improve their chances of developing successful new drugs.


----- Transcript -----

Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's Head of U.S. BioPharma Research. Along with my colleagues bringing you a variety of perspectives, today, I'll focus on how artificial intelligence and machine learning can reshape the health care sector. It's Thursday, July 6th at 10 a.m. in New York.


As we've discussed on this podcast, Tech Diffusion is one of the big three themes we at Morgan Stanley Research are following this year. The other two being the Multipolar World and Decarbonization. As a quick reminder, by tech diffusion, we mean the process by which any transformative technology is adopted widely by consumers and industries.


When it comes to the healthcare sector, it's still early but we believe artificial intelligence and machine learning adoption is poised to accelerate significantly. The biopharma industry specifically is moving to unlock the potential of A.I across multiple areas, including drug discovery, clinical development, manufacturing and physician patient engagement.


We see two broad areas where A.I enabled investments in drug development could drive significant value in the biopharma space. One is direct cost savings, so think of improved R&D margins, for example. And two is increased probability of success of pipeline programs. Here we estimate that even small improvements in the probability of success could drive significant value.


Now, let me put some numbers around this. Over the past ten years, the FDA has granted 430 new drug approvals or about 43 per year. We estimate that every two and a half percentage point improvement in early stage development success rates could lead to an additional 30 new drug approvals over the course of ten years, or nearly a 10% boost. Assuming that each incremental approved drug generates over 600 million in peak sales, we estimate that 60 additional therapies approved over a ten year period would translate into an additional 70 billion in drug development and PV for the biopharma industry.


However, biopharma is not the only health care subsector that's poised to benefit from A.I.. Looking at health care services and technology, A.I represents an opportunity to drive meaningful change in efficiency in how care is delivered. A.I tools have predictive capabilities that could be used for early diagnosis and detection of disease, which could lead to improved clinical outcomes and patient experience and reduce the cost of care over time. Many health systems have already begun to migrate data from on premises to the cloud, an important step for capturing the full benefits of A.I.


We will continue to monitor further developments in health care, both near-term and long term, and will provide you with our latest analysis and insights.


Thanks for listening. If you enjoy the show, please leave us a review on Apple Podcasts and share Thoughts on the Market with a friend or colleague today.

Episoder(1511)

Michael Zezas: How Do Markets View Major Policy Proposals? (Replay)

Michael Zezas: How Do Markets View Major Policy Proposals? (Replay)

On today's episode, Head of U.S. Public Policy Michael Zezas takes a look at transformative policy proposals by 2020 Presidential candidates. How could big policies like Medicare-for-All reshape markets?

30 Okt 20192min

Mike Wilson: Are U.S. Equities Defying Gravity?

Mike Wilson: Are U.S. Equities Defying Gravity?

On today’s episode, a curious paradox: Although major indices are making new highs, many defensive stocks are leading the pack. Chief Investment Officer Mike Wilson explains why.

28 Okt 20193min

Andrew Sheets: Can Sentiment Alone Drive Markets Higher?

Andrew Sheets: Can Sentiment Alone Drive Markets Higher?

On today's episode, Optimism in markets has risen significantly over the past three weeks. But Chief-Across Asset Strategist Andrew Sheets asks, “Is optimism enough?”

25 Okt 20193min

Michael Zezas: Could “Phase One” Be the Turning Point?

Michael Zezas: Could “Phase One” Be the Turning Point?

On this episode, Head of U.S. Public Policy Michael Zezas explains why a global growth rebound could largely hinge on trade negotiations ahead of the December 15th tariffs.

23 Okt 20191min

Mike Wilson: 5 Pockets of Opportunity for Equities Investors

Mike Wilson: 5 Pockets of Opportunity for Equities Investors

On today's episode, Chief Investment Officer Mike Wilson says investors may want to steer clear of expensive growth stocks in favor of some defensive and cheaper-priced stocks.

21 Okt 20193min

Andrew Sheets: One Market We Feel Good About

Andrew Sheets: One Market We Feel Good About

On today’s episode, Chief Cross Asset Strategist Andrew Sheets highlights the one market in which the currency, government bonds and equities may all be solid defensive plays.

18 Okt 20192min

Michael Zezas: A “Durable Pause” on U.S.-China Trade Tensions?

Michael Zezas: A “Durable Pause” on U.S.-China Trade Tensions?

On today’s episode, Head of Public Policy Michael Zezas says unlike prior tariff pauses, the “phase one” agreement could have durability. However, much uncertainty remains.

16 Okt 20192min

Mike Wilson: How Will the “Phase One” Trade Deal Impact Earnings?

Mike Wilson: How Will the “Phase One” Trade Deal Impact Earnings?

On today's episode, Chief Investment Officer Mike Wilson says the U.S.-China trade deal is a step in the right direction, but the real story is still the corporate profits outlook.

14 Okt 20193min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
e24-podden
kommentarer-fra-aftenposten
rss-borsmorgen-okonominyhetene
rss-penger-polser-og-politikk
finansredaksjonen
livet-pa-veien-med-jan-erik-larssen
rss-vass-knepp-show
pengepodden-2
tid-er-penger-en-podcast-med-peter-warren
okonomiamatorene
stormkast-med-valebrokk-stordalen
utbytte
morgenkaffen-med-finansavisen
rss-sunn-okonomi
lederpodden
aksjepodden
shifter
rss-fa-makro